The U.S. Food and Drug Administration (FDA) has granted approval for Hibsago, a new therapeutic treatment for chronic hepatitis B developed by GSK. The medication, which utilizes the active ingredient bepirovirsen, aims to achieve a functional cure by suppressing the virus to undetectable levels in patients even after the conclusion of treatment.
Clinical Realities of the Bepirovirsen Regimen
- Functional Cure Definition: The treatment suppresses the virus to levels that are not detectable in blood tests, though it does not eradicate every trace of the virus from the body.
- Treatment Protocol: Patients receive weekly injections for a six-month duration, administered alongside their existing oral antiviral medications.
- Post-Treatment Status: Once the six-month course is complete, patients may be eligible to discontinue both the injection and their pre-existing oral medications under medical supervision.
Efficacy Data from Phase III Trials
The regulatory approval follows data published in The New England Journal of Medicine. In two Phase III clinical trials involving a total of 1,220 participants, 233 individuals—approximately 19%—achieved a functional cure. Notably, none of the 614 participants who received a placebo reached this outcome. For those who responded to the treatment, the virus remained undetectable for at least 24 weeks following the cessation of all therapies. This represents a 72-week milestone from the start of the study, though long-term durability beyond this period remains a subject for ongoing observation.
Hibsago Targets Hepatitis B to Achieve Functional Cure
Hibsago functions by targeting the hepatitis B virus directly to reduce its viral load. Norah Terrault, a gastroenterologist at the Keck Medical Center of the University of Southern California, noted that Hibsago provides patients with the potential to reach a functional cure following a relatively short treatment window.
| Metric | Hibsago (Bepirovirsen) Group | Placebo Group |
|---|---|---|
| Total Participants | 1,220 (Trial aggregate) | 614 |
| Post-Treatment Monitoring | 24 weeks | 24 weeks |
Monitor Liver Health During Treatment and Consult Specialists
During the clinical trials, some participants experienced severe side effects, including liver inflammation. Because of the potential for hepatic (liver) distress, the FDA mandates rigorous monitoring through regular blood work for all patients undergoing the regimen. Chronic hepatitis B itself carries long-term risks, including cirrhosis (scarring of the liver), liver failure, and hepatocellular carcinoma. Patients currently managing the infection should consult their hepatologist or gastroenterologist to determine if their specific viral profile makes them a candidate for this therapy, particularly given the necessity of pre-treatment screening for viral protein markers.
Future Trajectory and Global Access
GSK has indicated that its research pipeline includes evaluating combination therapies to potentially increase the efficacy rate of Hibsago. Beyond the current regulatory framework in the United States, the company has expressed an intention to expand the availability of the medication to international markets. Current standard-of-care treatments for chronic hepatitis B typically involve the long-term, often multi-year, administration of antivirals to manage viral replication. The shift toward a finite, six-month treatment protocol represents a change in the management of the condition, though the medical community awaits further longitudinal data to confirm if these undetectable viral levels persist over several years.
The FDA has cleared GSK’s Hibsago (bepirovirsen), delivering the first 24-week functional cure regimen for chronic hepatitis B. The biology is a triumph, but the label exposes the commercial friction: – Indication gated strictly to baseline HBsAg < 3,000 IU/ml via authorized…
More on Drug Administration
HEPATITIS B BREAKTHROUGH! COULD WE FINALLY BE MOVING TOWARD A FUNCTIONAL CURE? For decades, physicians have been able to suppress hepatitis B, but achieving a sustained functional cure has remained extremely difficult. That may finally be changing! On October 20, 2026, the FDA… pic.twitter.com/FD4KV9Ween
Big news for hepatitis B! After the remarkable success of curing hepatitis C, we are finally making real progress toward a functional cure for hepatitis B! The FDA just approved bepirovirsen (Hibsago), a first-in-class antisense oligonucleotide, following two phase 3 trials… pic.twitter.com/GFwA6Tk78r
FDA Approves Hepatitis B Breakthrough—but at What Risk? GSK’s Hibsago achieved a functional cure in 19% of patients, but serious adverse events occurred in 7% vs. 4% on placebo. https://t.co/0G33mVWuvN
FDA Approves Hibsago First Drug That May Let Some Hep B Patients Stop Treatment On Oct 20, 2026, the FDA approved Hibsago (bepirovirsen) by GSK the first-ever antisense oligonucleotide for chronic Hepatitis B. Instead of just suppressing the virus like current daily pills, it… pic.twitter.com/SNVC6oWos1
